Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients

M. Garami, D. Schuler, Mária Babosa, Gábor Borgulya, P. Hauser, J. Müller, András Paksy, Eniko Szabó, M. Hídvégi, G. Fekete

Research output: Article

29 Citations (Scopus)

Abstract

Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC. Methods: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM = T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups. Results: During the treatment (follow-up) period, there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P <0.05). Conclusions: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers.

Original languageEnglish
Pages (from-to)631-635
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume26
Issue number10
DOIs
Publication statusPublished - okt. 2004

Fingerprint

Chemotherapy-Induced Febrile Neutropenia
Pediatrics
Neoplasms
Febrile Neutropenia
Therapeutics
Fever
Antipyretics
Central Venous Catheters
Neoplasm Staging
Incidence
Nonparametric Statistics
Avemar
Disease Progression
Clinical Trials
Neoplasm Metastasis
Anti-Bacterial Agents
Drug Therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

@article{a6c6d29261fa4a7ab3f7d1c0ec6149ca,
title = "Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients",
abstract = "Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC. Methods: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM = T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups. Results: During the treatment (follow-up) period, there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8{\%}) in the MSC group versus 46 (43.4{\%}) in the control group (Wilcoxon signed rank test, P <0.05). Conclusions: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers.",
keywords = "Febrile neutropenia, Fermented wheat germ extract, Pediatric cancer",
author = "M. Garami and D. Schuler and M{\'a}ria Babosa and G{\'a}bor Borgulya and P. Hauser and J. M{\"u}ller and Andr{\'a}s Paksy and Eniko Szab{\'o} and M. H{\'i}dv{\'e}gi and G. Fekete",
year = "2004",
month = "10",
doi = "10.1097/01.mph.0000141897.04996.21",
language = "English",
volume = "26",
pages = "631--635",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients

AU - Garami, M.

AU - Schuler, D.

AU - Babosa, Mária

AU - Borgulya, Gábor

AU - Hauser, P.

AU - Müller, J.

AU - Paksy, András

AU - Szabó, Eniko

AU - Hídvégi, M.

AU - Fekete, G.

PY - 2004/10

Y1 - 2004/10

N2 - Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC. Methods: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM = T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups. Results: During the treatment (follow-up) period, there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P <0.05). Conclusions: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers.

AB - Purpose: An open-label, matched-pair (by diagnosis, stage of disease, age, and gender) pilot clinical trial was conducted to test whether the combined administration of the medical nutriment MSC (Avemar) with cytotoxic drugs and the continued administration of MSC on its own help to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers compared with the same treatments without MSC. Methods: Between December 1998 and May 2002, 22 patients (11 pairs) were enrolled in this study. At baseline, the staging of the tumors was the same in each pair (mostly pTNM = T2N0M0), with the exception of two cases in which patients in the MSC group had worse prognoses (metastasis at baseline). There were no significant differences in the average age of the patients, the length of treatment time (MSC) or follow-up, the number of patients with central venous catheters, the number of chemotherapy cycles, the frequency of preventive counterneutropenic interventions, or the type and dosage of antibiotic and antipyretic therapy used in the two groups. Results: During the treatment (follow-up) period, there was no progression of the malignant disease, whereas at end-point the number and frequency of febrile neutropenic events significantly differed between the two groups: 30 febrile neutropenic episodes (24.8%) in the MSC group versus 46 (43.4%) in the control group (Wilcoxon signed rank test, P <0.05). Conclusions: The continuous supplementation of anticancer therapies with the medical nutriment MSC helps to reduce the incidence of treatment-related febrile neutropenia in children with solid cancers.

KW - Febrile neutropenia

KW - Fermented wheat germ extract

KW - Pediatric cancer

UR - http://www.scopus.com/inward/record.url?scp=5344266147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5344266147&partnerID=8YFLogxK

U2 - 10.1097/01.mph.0000141897.04996.21

DO - 10.1097/01.mph.0000141897.04996.21

M3 - Article

C2 - 15454833

AN - SCOPUS:5344266147

VL - 26

SP - 631

EP - 635

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 10

ER -